Fentanyl transmucosal - Teva Pharmaceutical Industries

Drug Profile

Fentanyl transmucosal - Teva Pharmaceutical Industries

Alternative Names: Actiq; TA-8317

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cephalon
  • Developer Mitsubishi Tanabe Pharma Corporation
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain

Most Recent Events

  • 08 Aug 2013 Biomarkers information updated
  • 21 Jul 2011 US FDA approves a Risk Evaluation and Mitigation Strategy for fentanyl transmucosal
  • 29 Oct 2010 Registered for Cancer pain in Japan (Transmucosal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top